Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.
Hideki IwamotoShigeo ShimoseYu NodaTomotake ShironoTakashi NiizekiMasahito NakanoShusuke OkamuraNaoki KamachiHiroyuki SuzukiMiwa SakaiAkira KajiwaraSatoshi ItanoMasatoshi TanakaTaizo YamaguchiRyoko KuromatsuHironori KogaTakuji Torimuranull On Behalf Of The Kurume Liver Cancer Study Group Of JapanPublished in: Cancers (2021)
The study demonstrated that atezolizumab plus bevacizumab was effective and safe for patients with HCC even in the real-world setting including patients with a previous MTA history or other than ALBI grade 1.